Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC)

Detalles Bibliográficos
Autores principales: Metro, Giulio, Bonaiti, Angelo, Birocchi, Ilaria, Marasciulo, Francesca, Ubaldi, Martina, Metelli, Niccolò, Minotti, Vincenzo, Addeo, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096286/
https://www.ncbi.nlm.nih.gov/pubmed/35572898
http://dx.doi.org/10.21037/jtd-22-98
_version_ 1784705941761949696
author Metro, Giulio
Bonaiti, Angelo
Birocchi, Ilaria
Marasciulo, Francesca
Ubaldi, Martina
Metelli, Niccolò
Minotti, Vincenzo
Addeo, Alfredo
author_facet Metro, Giulio
Bonaiti, Angelo
Birocchi, Ilaria
Marasciulo, Francesca
Ubaldi, Martina
Metelli, Niccolò
Minotti, Vincenzo
Addeo, Alfredo
author_sort Metro, Giulio
collection PubMed
description
format Online
Article
Text
id pubmed-9096286
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-90962862022-05-13 Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) Metro, Giulio Bonaiti, Angelo Birocchi, Ilaria Marasciulo, Francesca Ubaldi, Martina Metelli, Niccolò Minotti, Vincenzo Addeo, Alfredo J Thorac Dis Editorial AME Publishing Company 2022-04 /pmc/articles/PMC9096286/ /pubmed/35572898 http://dx.doi.org/10.21037/jtd-22-98 Text en 2022 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Editorial
Metro, Giulio
Bonaiti, Angelo
Birocchi, Ilaria
Marasciulo, Francesca
Ubaldi, Martina
Metelli, Niccolò
Minotti, Vincenzo
Addeo, Alfredo
Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC)
title Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC)
title_full Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC)
title_fullStr Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC)
title_full_unstemmed Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC)
title_short Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC)
title_sort tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (egfr)-mutant non-small cell lung cancer (nsclc)
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096286/
https://www.ncbi.nlm.nih.gov/pubmed/35572898
http://dx.doi.org/10.21037/jtd-22-98
work_keys_str_mv AT metrogiulio trackingandtacklingthetumordynamicsclonalevolutionosimertinibrechallengeafterintervaltherapymightbeaneffectivetreatmentapproachinepidermalgrowthfactorreceptoregfrmutantnonsmallcelllungcancernsclc
AT bonaitiangelo trackingandtacklingthetumordynamicsclonalevolutionosimertinibrechallengeafterintervaltherapymightbeaneffectivetreatmentapproachinepidermalgrowthfactorreceptoregfrmutantnonsmallcelllungcancernsclc
AT birocchiilaria trackingandtacklingthetumordynamicsclonalevolutionosimertinibrechallengeafterintervaltherapymightbeaneffectivetreatmentapproachinepidermalgrowthfactorreceptoregfrmutantnonsmallcelllungcancernsclc
AT marasciulofrancesca trackingandtacklingthetumordynamicsclonalevolutionosimertinibrechallengeafterintervaltherapymightbeaneffectivetreatmentapproachinepidermalgrowthfactorreceptoregfrmutantnonsmallcelllungcancernsclc
AT ubaldimartina trackingandtacklingthetumordynamicsclonalevolutionosimertinibrechallengeafterintervaltherapymightbeaneffectivetreatmentapproachinepidermalgrowthfactorreceptoregfrmutantnonsmallcelllungcancernsclc
AT metelliniccolo trackingandtacklingthetumordynamicsclonalevolutionosimertinibrechallengeafterintervaltherapymightbeaneffectivetreatmentapproachinepidermalgrowthfactorreceptoregfrmutantnonsmallcelllungcancernsclc
AT minottivincenzo trackingandtacklingthetumordynamicsclonalevolutionosimertinibrechallengeafterintervaltherapymightbeaneffectivetreatmentapproachinepidermalgrowthfactorreceptoregfrmutantnonsmallcelllungcancernsclc
AT addeoalfredo trackingandtacklingthetumordynamicsclonalevolutionosimertinibrechallengeafterintervaltherapymightbeaneffectivetreatmentapproachinepidermalgrowthfactorreceptoregfrmutantnonsmallcelllungcancernsclc

Ejemplares similares